IP Library Granted Patent US 8,524,238
Granted Patent B2
US 8,524,238 · App. 13/436,411 · Granted Sep 3, 2013

Cancer targets and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,238
App. No.
13/436,411
Granted
Sep 3, 2013
Kind
B2
Abstract

Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.

Claims (4)

1. A method of inhibiting proliferation of colon cancer cells in vitro, the method comprising contacting the colon cancer cells in vitro with an isolated antibody that selectively binds to an angiopoietin-like 4 (ANGPTL4) protein to thereby inhibit proliferation of the colon cancer cells in vitro.

2. The method of claim 1 , wherein the amino acid sequence of the ANGPTL4 protein comprises a sequence selected from the group consisting of SEQ ID NOS:476-478.

3. The method of claim 1 , wherein the antibody is coupled to at least one agent selected from the group consisting of chemotherapeutic agents, cytotoxic agents, immunomodulatory agents, radiotherapeutic agents, differentiation inducers, anti-tubulin agents, auristatins, maytansinoids, toxins, and radionuclides.

4. The method of claim 2 , wherein the antibody is coupled to at least one agent selected from the group consisting of chemotherapeutic agents, cytotoxic agents, immunomodulatory agents, radiotherapeutic agents, differentiation inducers, anti-tubulin agents, auristatins, maytansinoids, toxins, and radionuclides.